Although dyspnea and anti-Ro52 antibodies are associated with ILD at multivariate analysis, anti-Ro52 antibodies define a subgroup of ILD-IIM with significant improvement during follow-up. This evidence concerns the gene TRIM21 and interstitial lung disease.